Multiple Sclerosis Clinical Trials in Seattle, Washington
14 recruitingSeattle, Washington
Showing 1–14 of 14 trials
Recruiting
Phase 2
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
Multiple Sclerosis
Hoffmann-La Roche182 enrolled56 locationsNCT07074886
Recruiting
Phase 1
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
Multiple Sclerosis
AstraZeneca24 enrolled19 locationsNCT07224373
Recruiting
Phase 1
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
Myasthenia GravisMultiple SclerosisChronic Inflammatory Demyelinating Polyneuropathy
Kite, A Gilead Company52 enrolled3 locationsNCT07304154
Recruiting
Not Applicable
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
Relapsing Remitting Multiple Sclerosis
SetPoint Medical Corporation60 enrolled5 locationsNCT06796504
Recruiting
Not Applicable
Confirmatory Trial for Alleviating Fatigue in Multiple Sclerosis
FatigueMultiple Sclerosis
Accelerated Cure Project for Multiple Sclerosis2,000 enrolled6 locationsNCT06441617
Recruiting
Phase 3
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Multiple Sclerosis
Sanofi1,600 enrolled384 locationsNCT06141473
Recruiting
Phase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Relapsing Multiple Sclerosis
TG Therapeutics, Inc.800 enrolled46 locationsNCT05877963
Recruiting
Not Applicable
Factorial Optimization Trial to Test Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue
Multiple Sclerosis
University of Washington112 enrolled1 locationNCT06809192
Recruiting
Phase 3
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Multiple Sclerosis
Sanofi900 enrolled338 locationsNCT06141486
Recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
Myasthenia GravisMultiple Sclerosis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company120 enrolled35 locationsNCT06220201
Recruiting
Phase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
Relapsing Multiple SclerosisRelapsing Remitting Multiple SclerosisSecondary Progressive Multiple Sclerosis
National Institute of Allergy and Infectious Diseases (NIAID)156 enrolled22 locationsNCT04047628
Recruiting
Phase 2
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
Multiple Sclerosis
Eli Lilly and Company200 enrolled50 locationsNCT06220669
Recruiting
Phase 1
Non-invasive Electrical Spinal Cord Stimulation To Restore Upper Extremity Function in Multiple Sclerosis
Multiple Sclerosis
University of Washington4 enrolled1 locationNCT06552611
Recruiting
Not Applicable
Increasing Physical Activity for Adults With Multiple Sclerosis (MS)
Physical InactivityFatigueMultiple Sclerosis (MS)
University of Washington106 enrolled1 locationNCT06270641